<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>Operator_BCSC1920_S01_C04_p071_080_5P</title>
		<link href="Operator_BCSC1920_S01_C04_p071_080_5P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="Operator_BCSC1920_S01_C04_p071_080_5P" lang="en-US">
		<div id="_idContainer001" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter</span><span class="cn-chap"> </span>4</p>
			<p class="chapter-title">Hypercholesterolemia and Cardiovascular Risk</p>
			<p class="h1 ParaOverride-1">Highlights</p>
			<div id="Chapt4_Top1">
			<p class="body-text--no-indent-">
			<ul>
				<li class="bullet-list-first ParaOverride-2">Therapeutic lifestyle changes remain an essential modality in the management of hyperlipidemia.</li>
				<li class="bullet-list-mid">More aggressive management of serum cholesterol and modifiable risk &#173;factors has been emphasized by the US National Cholesterol Education Program (NCEP) and the Eu&#173;ro&#173;pean Society of Cardiology (ESC).</li>
				<li class="bullet-list-mid">A number of tools (eg, HeartScore, the American Heart Association’s pooled cohort equations, QRISK, MESA) are available to assess the cardiovascular risk for an individual patient.</li>
				<li class="bullet-list-mid">Numerous clinical &#173;trials have shown that effective reduction of low-&#173;density-&#173;lipoprotein cholesterol (LDL-&#173;C) levels substantially reduces the risk of coronary heart disease and stroke.</li>
				<li class="bullet-list-mid">Patients at very-&#173;high risk of a cardiovascular event benefit from an LDL-&#173;C reduction of at least 50% or below 70&#160;mg/dL.</li>
				<li class="bullet-list-mid">Statin therapy is recommended for most dyslipoproteinemic adult patients with cardiometabolic risk.</li>
				<li class="bullet-list-last ParaOverride-3">Use of statins in acute coronary syndromes reduces the risk of recurrent coronary events.</li>
			</ul>
			</p>
			</div>
			<p class="h1">Introduction</p>
			<div id="Chapt4_Top2">
			<p class="body-text--no-indent-">Coronary heart disease (CHD) is the leading cause of death in the United States and in most of the developed world, accounting for more deaths than all forms of cancer combined. Numerous major studies have confirmed earlier reports that lowering elevated LDL-&#173;C levels reduces the risk of CHD. The NCEP provided 3 sets of guidelines for treating elevated blood cholesterol levels in adults: Adult Treatment Panel (ATP) I, II, and III. ATP I proposed a strategy for primary prevention of CHD in persons with high levels of LDL-&#173;C (<span class="symbol">≥</span>160&#160;mg/dL) or with borderline high levels of LDL-&#173;C (130–159&#160;mg/dL) and multiple (at least 2) risk &#173;factors (discussed in <span class="xref-local">the section Risk Assessment</span>). ATP II added intensive management of LDL-&#173;C in persons with established CHD. The ATP III guidelines recommended total cholesterol levels of less than 200&#160;mg/dL, LDL cholesterol levels of less than 100&#160;mg/dL, HDL cholesterol levels that are greater than or equal to 60&#160;mg/dL (for HDL, more is better), and triglyceride levels of less than 150&#160;mg/dL.</p>
			<p class="body-text">In 2013, a series of reports published in the United States questioned the value of &#173;having specific targets for LDL-&#173;C levels. &#173;These reports instead recommended the individual assessment of each patient’s cardiovascular risk, followed by aggressive treatment with statin drugs in &#173;those most likely to benefit. &#173;These recommendations are discussed <span class="xref-local">&#173;later in this chapter</span>.</p>
			</div>
			<p class="h1">Lipoproteins, Cholesterol, and Cardiovascular Disease</p>
			<div id="Chapt4_Top3">
			<p class="body-text--no-indent-">Cholesterol and triglycerides are transported in the body by <span class="italic">lipoproteins.</span> The vari&#173;ous classes of lipoprotein differ in the relative concentrations of their components: cholesterol, triglycerides, phospholipids, and proteins <span class="italic">(apolipoproteins).</span> Chylomicrons carry triglycerides following dietary lipid absorption, whereas <span class="italic">very-&#173;low-&#173;density lipoproteins (VLDLs),</span> which are produced by the liver, carry most circulating triglycerides. LDL, or “bad cholesterol,” is a product of the metabolism of VLDL and intermediate-&#173;density lipoprotein and is the primary carrier of cholesterol. High-&#173;density lipoprotein (HDL), or “good cholesterol,” is the smallest and densest lipoprotein particle. The result of the inflammatory interaction among &#173;these lipoproteins, macrophages, and the cellular components of the arterial wall is called <span class="italic">atherosclerosis.</span> Although patients’ cholesterol levels are what is typically mea&#173;sured, it is the lipoproteins that interact with the arterial wall, producing plaques. The narrowing of the arterial lumen that results from plaque growth or the rupture of a plaque with subsequent thrombosis leads to cardiovascular disease (CVD), including myo&#173;car&#173;dial infarction (MI), stroke, and peripheral arterial disease.</p>
			</div>
			<p class="h1">Risk Assessment</p>
			<div id="Chapt4_Top4">
			<p class="body-text--no-indent-">The cholesterol level of approximately half the US population puts &#173;these individuals at significant risk. A fasting lipoprotein profile (mea&#173;sur&#173;ing total cholesterol, LDL-&#173;C, HDL-&#173;C, and triglyceride levels) helps determine an individual’s risk status. The US Preventive Ser&#173;vices Task Force recommends screening for lipid disorders in men 20–35&#160;years of age and &#173;women aged 45&#160;years and older when other risk &#173;factors exist, and all men aged 35&#160;years and older regardless of other risk &#173;factors. Experimental studies directly support the central role of LDL in atherogenesis, and lowering LDL-&#173;C levels is associated with a reduction in CVD risk. Conversely, HDL-&#173;C appears protective against atherosclerosis &#173;because of its anti-&#173;inflammatory properties and its ability to transport cholesterol from vessel walls to the liver for disposal. In general, current guidelines recommend a high-&#173;HDL and low-&#173;LDL concentration to decrease CVD risk.</p>
			<p class="body-text">Other CHD risk &#173;factors, such as hypertension, smoking, diabetes mellitus, short sleep duration, obesity, and limited physical activity should be assessed and managed appropriately in all adults (<span class="xref-table">&#173;Table&#160;4-1</span>). The INTERHEART study, which involved 15,000 patients with acute MI versus 15,000 controls in 52 countries, found that current smoking, hypertension, diabetes mellitus, abdominal obesity, psychosocial &#173;factors, and a raised apolipoprotein &#173;B/apolipoprotein A-&#173;I ratio increased the risk of acute MI, while moderate or strenuous exercise, daily consumption of fruits and vegetables, and daily consumption of small amounts of alcohol &#173;were protective.</p>
			<p class="body-text">A number of risk assessment tools are available to estimate the 10-&#173;year risk of a cardiovascular event, including the pooled cohort equations on the American Heart Association (AHA) website (United States); QRISK (United Kingdom); HeartScore (Eu&#173;rope); and MESA (Multi-&#173;Ethnic Study of Atherosclerosis; United States). Physicians are encouraged to use the risk tool best suited to the individual patient, &#173;because relative cardiac risk varies among national, ethnic, and racial groups. Use of &#173;these tools guides the clinician in identifying patients requiring aggressive treatment and &#173;those most likely to benefit from such treatment.</p>
			<p class="reference--journal--first">2013 prevention guidelines tools: CV risk calculator (pooled cohort equations). AHA website. <a href="http://professional.heart.org/professional/GuidelinesStatements/PreventionGuidelines/UCM_457698_Prevention-Guidelines.jsp">http://&#173;professional.&#173;heart.&#173;org/&#173;professional/&#173;GuidelinesStatements/&#173;PreventionGuidelines/&#173;UCM_&#173;457698_&#173;Prevention-&#173;Guidelines.&#173;jsp</a>. Accessed February 21, 2019.</p>
			<p class="reference--journal--mid">Goff DC Jr, Lloyd-&#173;Jones DM, Bennet G, et&#160;al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <span class="italic">Circulation.</span> 2014; <br />129(25 Suppl 2):S49–73.</p>
			<p class="reference--journal--mid">Graham I, Atar D, Borch-&#173;Johnsen K, et&#160;al; Eu&#173;ro&#173;pean Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). Eu&#173;ro&#173;pean guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth joint task force of the Eu&#173;ro&#173;pean Society of Cardiology and other socie&#173;ties on cardiovascular disease prevention in clinical practice (constituted by representatives of nine socie&#173;ties and by invited experts). <span class="italic">Eur Heart&#160;J.</span> 2007; 28(19):2375–2414.</p>
			<p class="reference--non-journal--mid">HeartScore. Eu&#173;ro&#173;pean Association of Preventive Cardiology website. <a href="http://www.heartscore.org/en_GB">www.&#173;heartscore.&#173;org/&#173;en_&#173;GB</a>. Accessed February 21, 2019.</p>
			<p class="reference--non-journal--mid">MESA risk calculator. <a href="https://mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx">https://&#173;mesa-&#173;nhlbi.&#173;org/&#173;MESACHDRisk/&#173;MesaRiskScore/&#173;RiskScore.&#173;aspx</a>. Accessed February 21, 2019.</p>
			<p class="reference--non-journal--last ParaOverride-4">QRISK3-2018 risk calculator. ClinRisk website. <a href="http://qrisk.org/three">http://&#173;qrisk.&#173;org/&#173;three</a>. Accessed February 21, 2019.</p>
			</div>
			<p class="h1">Management</p>
			<div id="Chapt4_Top5">
			<p class="body-text--no-indent-">In its simplest terms, the management of hyperlipidemia consists of matching the intensity of LDL-&#173;lowering therapy with the absolute risk: the higher the risk, the lower the target LDL level. This approach is based primarily on data from clinical &#173;trials and epidemiological studies, which, as mentioned previously, have suggested that a direct relationship exists between the level of LDL-&#173;C and the risk of CHD. The ATP III guidelines suggested mea&#173;sur&#173;ing fasting lipoprotein levels in patients with hyperlipidemia and/or &#173;hyperlipoproteinemia. The clinician should also assess the patient for the presence of other risk &#173;factors (see <span class="xref-local">&#173;Table&#160;4-1</span>) and the presence of clinical atherosclerotic disease, including clinical CHD, cerebrovascular or peripheral arterial disease, or abdominal aortic aneurysm. A risk calculator can help the clinician determine a patient’s 10-&#173;year risk for CHD based on &#173;these &#173;factors on a scale from lower risk to high risk. LDL treatment goals are determined based on the patient’s risk level. When treatment with a statin drug is indicated, the 2013 guidelines from the American College of Cardiology and the American Heart Association (ACC/AHA) recommend that patients be given the maximum tolerated intensity of the statin. Similarly, in 2016, the Eu&#173;ro&#173;pean Society of Cardiology recommended that each patient undergo a risk assessment (systematic coronary risk evaluation, or SCORE) and lowering of LDL cholesterol levels to 100&#160;mg/dL in high-&#173;risk patients and 70&#160;mg/dL in very-&#173;high-&#173;risk patients. &#173;These groups no longer advocate treatment to a preset generalized goal but instead recognize that any reduction in LDL-&#173;C is beneficial, and that some patients should be treated more aggressively &#173;because of their higher cardiovascular risk.</p>
			<p class="body-text">Therapeutic lifestyle changes, including dietary modifications, weight management, and increased physical activity, should be initiated. A diet high in fruits, vegetables, fiber, omega-3 fatty acids, and foods with a low glycemic index, and substituting mono&#173;unsaturated fats for polyunsaturated or trans fats, have repeatedly been shown to lower cardiovascular risk. If LDL goals are not achieved by lifestyle changes alone, drug therapy should be introduced and, if necessary, advanced. Current US and Eu&#173;ro&#173;pean guidelines strongly support the use of statin drugs as the primary intervention. <span class="xref-table">&#173;Tables&#160;4-2</span> and <span class="xref-table">4-3 pres&#173;ent information about</span> specific drugs, their lipid-&#173;lowering effects, and pos&#173;si&#173;ble adverse effects.</p>
			<p class="body-text">Once the goal LDL levels have been achieved, other lipid and nonlipid risk &#173;factors can be modified. Elevated triglyceride levels may respond to increased physical activity or weight management, but if the triglyceride levels are greater than or equal to 200&#160;mg/dL &#173;after the LDL goal is reached, a secondary treatment goal would be a non–&#173;HDL-&#173;C (total – &#173;HDL) level of 30&#160;mg/dL higher than the LDL goal.</p>
			<p class="reference--journal--first">Eckel RH, Jakicic JM, Ard JD, et&#160;al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <span class="italic">Circulation</span>. 2014; 129(25 Suppl 2):S76–99.</p>
			<p class="reference--journal--last ParaOverride-4">Catapano AL, Graham I, De Backer G, et&#160;al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. <span class="italic">Eur Heart J</span>. 2016; 37(39):2999–3058.</p>
			<p class="h2 ParaOverride-5">The Role of Statins</p>
			<p class="body-text--no-indent-">For virtually all patients whose LDL-&#173;C goals cannot be achieved by therapeutic lifestyle changes alone, 3-&#173;hydroxy-3-&#173;methylglutaryl coenzyme A (HMG-&#173;CoA) reductase inhibitors, more popularly known as <span class="italic">statins,</span> are the first choice for medical therapy. Multiple &#173;trials involving the use of statin drugs have reinforced the value of LDL-&#173;lowering therapy in reducing the risk of cardiometabolic disease. Moreover, the statins are the only class of oral drugs whose use has been shown to improve overall mortality in primary and secondary prevention. The Heart Protection Study, Myo&#173;car&#173;dial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) study, and the PROVE IT study, among &#173;others, each demonstrated a decreased risk of major cardiovascular events in patients whose LDL-&#173;C levels had been lowered with statins. Findings from the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) suggest that statins—&#173;which are known to lower C-&#173;reactive protein levels in addition to having positive effects on hyperlipidemia—&#173;may decrease the risk of stroke, coronary artery disease, and death in apparently healthy persons without hyperlipidemia but with a C-&#173;reactive protein level greater than 2.0&#160;mg/L. The beneficial effects of statins arise from the reduction of LDL-&#173;C levels, stabilization of atherosclerotic plaques, and decreased atherogenic inflammation.</p>
			<p class="body-text">The 2013 ACC/AHA guidelines identified 4 patient groups likely to benefit from statin use:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-6">individuals with clinical atherosclerotic cardiovascular disease (ASCVD)</li>
				<li class="bullet-list-mid">individuals with LDL-&#173;C levels of <span class="symbol">≥</span>190&#160;mg/dL</li>
				<li class="bullet-list-mid">individuals aged 40–75&#160;years with diabetes (but without ASCVD) and LDL-&#173;C levels of 70–189&#160;mg/dL</li>
				<li class="bullet-list-last ParaOverride-7">individuals aged 40–75&#160;years without diabetes or ASCVD with LDL-&#173;C levels of 70–189&#160;mg/dL and an estimated 10-&#173;year ASCVD risk of <span class="symbol">&gt;</span>7.5%.</li>
			</ul>
			<p class="body-text">In &#173;these patients, the ACC/AHA recommendation is moderate to maximal intensity statin therapy (<span class="xref-local">see &#173;Table&#160;4-3</span>), while &#173;those intolerant of high-&#173;intensity therapy or &#173;those at lower estimated cardiovascular risk may be treated with moderate intensity therapy. Current ESC and other international guidelines are similar, and they also recommend assessment of the risk for each patient with LDL-&#173;C goals tailored to the patient’s level of cardiovascular risk. Large studies have not established exact LDL-&#173;C goals, but many study authors recommend an LDL-&#173;C of less than 100&#160;mg/dL for high-&#173;risk patients and less than 70&#160;mg/dL in very-&#173;high-&#173;risk individuals.</p>
			<p class="body-text">Other drugs used to lower LDL-&#173;C levels (<span class="xref-local">see &#173;Table&#160;4-2</span>) include nicotinic acid, bile acid sequestrants, fibric acids, and cholesterol absorption inhibitors. Although many of &#173;these drugs have been shown to lower LDL-&#173;C levels, &#173;there is a general lack of large randomized controlled &#173;trials demonstrating their effects on ASCVD or mortality. &#173;These drugs are often used worldwide; however, the most recent ACC/AHA and ESC guidelines do not support the use of &#173;these drugs in place of statins when statin therapy is effective and well tolerated. The role of &#173;these drugs when added to high-&#173;intensity statin treatment is still to be elucidated. A new class of injectable drugs consisting of monoclonal antibodies to proprotein convertase subtilisin kexin 9 (PCSK9-&#173;abs) shows promise in lowering LDL levels and &#173;reducing the risk of CV events, even when added to maximal statin therapy. Although the PCSK9-&#173;abs agents have been shown to reduce LDL-&#173;C levels by 60%–70%, their expense and delivery method (injection) have limited their outpatient use thus far.</p>
			<p class="body-text">Although statin drugs are largely safe and effective, patients taking them must be monitored for serious adverse effects, especially in the first few months of treatment. Adverse effects of statin use are rare but can include elevated hepatic transaminases, diarrhea, liver failure, polyneuropathy, and myopathy. Simvastatin should not be started at or increased to&#160;a dose of 80&#160;mg per day &#173;because of the high risk of muscle injury. The risk of myopathy is also increased when simvastatin is used in conjunction with other medi&#173;cations, including amiodarone, some fibrates (gemfibrozil), and some calcium channel blockers. Cerivastatin was voluntarily withdrawn from the market &#173;after more than 52 reports of rhabdomyolysis and death related to its use. Pregnant &#173;women should not take statin drugs due to pos&#173;si&#173;ble teratogenic effects.</p>
			<p class="reference--journal--first">Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Ser&#173;vices Task Force. <span class="italic">JAMA.</span> 2016; 316(19):2008–2024.</p>
			<p class="reference--non-journal--mid">ESC Clinical Practice Guidelines. Eu&#173;ro&#173;pean Society of Cardiology website. <a href="http://www.escardio.org/Guidelines/Clinical-Practice-Guidelines">www.&#173;escardio.&#173;org/&#173;Guidelines/&#173;Clinical-&#173;Practice-&#173;Guidelines</a>. Accessed February 21, 2019.</p>
			<p class="reference--journal--last ParaOverride-4">Stone NJ, Robinson JG, Lichtenstein AH, et&#160;al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <span class="italic">Circulation.</span> 2014; 129(25 Suppl 2):S1–&#173;S45.</p>
			<p class="h2">Metabolic Syndrome</p>
			<p class="body-text--no-indent-">Metabolic syndrome comprises a constellation of lipid and nonlipid risk &#173;factors of metabolic origin. In 2006, the International Diabetes Federation developed a consensus definition for metabolic syndrome that includes central (abdominal) obesity (as mea&#173;sured by waist circumference), elevated triglyceride levels, high blood pressure, reduced HDL cholesterol, and elevated fasting blood glucose.</p>
			<p class="body-text">Metabolic syndrome is closely linked to insulin re&#173;sis&#173;tance. Excess body fat (particularly abdominal fat) and physical inactivity promote impaired responses to insulin; &#173;these impaired responses may also result from ge&#173;ne&#173;tic predisposition. The risk &#173;factors for metabolic syndrome are highly concordant; in aggregate, they increase the risk of CHD at any given LDL level. Management of metabolic syndrome includes &#173;those mea&#173;sures previously discussed for elevated LDL and triglyceride levels, as well as treatment of hypertension and the use of aspirin to reduce the prothrombotic state in CHD patients. For further discussion of metabolic syndrome, <span class="xref-local">please see Chapter&#160;2.</span></p>
			<p class="reference--journal--first">Alberti KG, Eckel RH, Grundy SM, et&#160;al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. <span class="italic">Circulation.</span> 2009; 120(16):1640–1645.</p>
			<p class="reference--non-journal--last ParaOverride-4">The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation website. <a href="http://www.idf.org/e-library/consensus-statements">www.&#173;idf.&#173;org/&#173;e-&#173;library/&#173;consensus-&#173;statements</a>. Published 2006. Accessed February 21, 2019.</p>
			<p class="sidebar2-text--first-"><span class="sidebar2-head"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;</span><span class="sidebar2-head"><span class="sidebar_orange">Ophthalmic considerations</span></span><span class="sidebar2-head"> </span>Hyperlipidemia is a significant risk &#173;factor for ischemic heart disease, cerebrovascular disease, and peripheral arterial disease. The ophthalmologist may be the first physician to detect or recognize manifestations of atherosclerosis, particularly transient monocular visual loss, ret&#173;i&#173;nal vascular emboli or occlusions, ischemic optic neuropathy, or cortical visual field deficits from a previous ce&#173;re&#173;bral infarction. Detection of atherosclerosis may initiate a diagnostic evaluation that reveals significant carotid artery stenosis or coronary artery disease.</p>
			<p class="sidebar2-text">Corneal arcus, a nonreversible lipid deposit at the corneal limbus, is associated with age and hyperlipidemia. In the Blue Mountains Eye Study, the presence of arcus in persons aged 49&#160;years and older was associated with higher total cholesterol and triglyceride levels.</p>
			<p class="sidebar2-text">The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was designed to assess the effect of tight glycemic, dyslipidemic, and blood pressure control on cardiovascular events in patients with type 2 diabetes. A subset of &#173;these patients (ACCORD EYE) was examined to assess the effects of this control on the progression of diabetic retinopathy (DR). Previous studies had shown mixed results of the effect of tight glycemic control on DR.&#160;In the ACCORD EYE study, the tight control of glycemia resulted in a 33% reduction in the relative risk of progression of DR, although it did not decrease the risk of moderate vision loss. Treating patients with simvastatin plus fenofibrate for dyslipidemia control yielded a 40% reduction in the risk of DR progression. Tight blood pressure control did not appear to affect DR progression in ACCORD. Previous studies (eg, the Fenofibrate Intervention and Event Lowering in Diabetes [FIELD] study) have also suggested a pos&#173;si&#173;ble protective effect of the use of fenofibrate on DR.</p>
			<p class="sidebar2-text">Statin use may also be associated with a reduction in intraocular pressure and potentially a protective effect against glaucoma. Additional clinical research is needed. Patients with ocular hypertension or glaucoma being treated with topical timolol have a small but statistically significant elevation of serum LDL and reduction in HDL, but do not appear to have increased mortality.</p>
			<p class="sidebar2-text">The relationship of statin use to age-&#173;related macular degeneration (AMD) is unresolved. Several population-&#173;based studies (Atherosclerosis Risk in Communities [ARIC], the Melbourne Collaborative Cohort Study, Blue Mountains Eye Study) have suggested that the use of statins is associated with a decreased risk of advanced AMD, whereas other studies (Beaver Dam, Age-&#173;Related Eye Disease Study 2 [AREDS2]) suggest &#173;there is no change in AMD risk with statin use. More data are required to assess the nature of this relationship.</p>
			<p class="sidebar2-text">The effect of statins on the development of cataracts is unclear. Although the Blue Mountains study suggested a protective effect, the AREDS2 study points to an increased risk of cataract development in patients taking a statin, particularly in women over age 75.</p>
			<p class="sidebar2-reference-first">Al-&#173;Holou SN, Tucker WR, Agron E, et&#160;al; Age-&#173;Related Eye Disease Study 2 Research Group. The association of statin use with age-&#173;related macular degeneration progres&#173;sion: The Age-&#173;Related Eye Disease Study 2 Report Number 9. <span class="italic">Ophthalmol.</span> 2015; 122(12):2490–2496.</p>
			<p class="sidebar2-reference-mid">Al-&#173;Holou SN, Tucker WR, Agron E et&#160;al; Age-&#173;Related Eye Disease Study 2 Research Group. The association of statin use with cataract progression and cataract surgery: The AREDS2 Report Number 8. <span class="italic">Ophthalmol</span>. 2016; 123(4):916–917.</p>
			<p class="sidebar2-reference-mid">American Acad&#173;emy of Ophthalmology website; <a href="http://www.aao.org">www.&#173;aao.&#173;org</a>.</p>
			<p class="sidebar2-reference-mid">American Heart Association website; <a href="http://www.heart.org">www.&#173;heart.&#173;org</a>.</p>
			<p class="sidebar2-reference-mid">CardioSource. American College of Cardiology website; <a href="http://www.acc.org">www.&#173;acc.&#173;org</a>.</p>
			<p class="sidebar2-reference-mid">Chew EY, Ambrosius WT, Davis MD, et&#160;al; ACCORD Study group, ACCORD Eye Study group. Effects of medical therapies on retinopathy progression in type 2 diabetes. <span class="italic">N </span><span class="italic">Engl J Med.</span> 2010; 363(3):233–244.</p>
			<p class="sidebar2-reference-mid">European Society of Cardiology website; <a href="http://www.escardio.org">www.&#173;escardio.&#173;org</a>.</p>
			<p class="sidebar2-reference-mid">Talwar N, Musch DC, Stein JD. Association of daily dosage and type of statin agent with risk of open-&#173;angle glaucoma. <span class="italic">JAMA Ophthalmol.</span> 2017; 135(3):263–267.</p>
			<p class="sidebar2-reference-last">Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statin use and the long-&#173;term risk of incident cataract: The Blue Mountains Eye Study. <span class="italic">Am J Ophthalmol.</span> 2007;143(4):687–689.</p>
		</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer002" class="Basic-Text-Frame">
			</div>
		</div>
		<div id="_idContainer003" class="Basic-Text-Frame">
			<table id="table001" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-3" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-4" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="5">
							<p class="table-title"><span class="table-number">&#173;Table&#160;4-1</span> Risk &#173;Factor Modification Treatment Goals</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Risk &#173;Factor</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Goal</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Intervention</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Blood pressure</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"><span class="symbol">&lt;</span>130/80&#160;mm Hg</p>
							<p class="table-body">Lower goal if patient has chronic kidney disease or diabetes mellitus</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Weight control, increased physical activity, alcohol moderation, sodium reduction, medi&#173;cations</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Smoking</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Smoking cessation</p>
							<p class="table-body">Avoid environmental tobacco smoke</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Smoking cessation programs, nicotine replacement, bupropion, varenicline</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Lipid management</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Decreased LDL-C with goal <br />based on overall cardio&#173;vascular risk</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Diet low in saturated fat, increased omega-3 fatty acids, weight control, increased physical activity, statins</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Diabetes mellitus</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">HbA<span class="subscript _idGenCharOverride-1">1c</span> <span class="symbol">&lt;</span>7% or tailored to individual patient</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Diet, weight control, oral hypoglycemic agents, insulin</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Physical activity</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">150 mins/week moderate exercise or 75 mins/week vigorous exercise</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Walking, biking, swimming, gardening, &#173;house&#173;hold work, weight training</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Weight management</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">BMI 18.5–24.9&#160;kg/m<span class="superscript _idGenCharOverride-1">2</span></p>
							<p class="table-body">Waist circumference:</p>
							<p class="table-indent-1"><span class="symbol">≤</span>102&#160;cm men</p>
							<p class="table-indent-1"><span class="symbol">≤</span>88&#160;cm &#173;women</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Physical activity, caloric intake, behavioral programs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-7" colspan="5">
							<p class="table-footnote ParaOverride-8">BMI <span class="symbol">=</span> body mass index; HbA<span class="subscript _idGenCharOverride-1">1c</span> <span class="symbol">=</span> hemoglobin A<span class="subscript _idGenCharOverride-1">1c</span>; HDL-C <span class="symbol">=</span> high-&#173;density-&#173;lipoprotein cholesterol; <br />LDL-C <span class="symbol">=</span> low-&#173;density-&#173;lipoprotein cholesterol.</p>
							<p class="table-source-note">Modified with permission from Smith S, Allen&#160;J. AHA/ACC secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2005 update. <span class="table-italic">Circulation.</span> 2006;113:2363–2372 (92).</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer004" class="Basic-Text-Frame">
			</div>
		</div>
		<div id="_idContainer005" class="Basic-Text-Frame">
			<table id="table002" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-15" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-16" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-17" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="7">
							<p class="table-title"><span class="table-number">&#173;Table&#160;4-2</span> Drugs Affecting Lipoprotein Metabolism</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Drug Class</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Agents</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Lipid/Lipoprotein Effects</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Adverse Effects</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">HMG-&#173;CoA reductase inhibitors</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Statins</p>
							<p class="table-body">(see &#173;Table&#160;4-3)</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">LDL <span class="symbol">↓</span> 20%–60%</p>
							<p class="table-body">HDL <span class="symbol">↑</span> 5%–10%</p>
							<p class="table-body">TG <span class="symbol">↓</span> 10%–30%</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Myopathy, increased levels of liver enzymes</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Bile acid sequestrants</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Cholestyramine</p>
							<p class="table-body">Colestipol</p>
							<p class="table-body">Colesevelam</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">LDL <span class="symbol">↓</span> 15%–30%</p>
							<p class="table-body">HDL <span class="symbol">↑</span> 3%–5%</p>
							<p class="table-body">TG no change or increase</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">GI distress, constipation, decreased absorption of other drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Nicotinic acid</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Immediate-&#173;, extended-,&#173; <br />or sustained-&#173;release nicotinic acid</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">LDL <span class="symbol">↓</span> 10%–25%</p>
							<p class="table-body">HDL <span class="symbol">↑</span> 15%–35%</p>
							<p class="table-body">TG <span class="symbol">↓</span> 20%–30%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Flushing, hyperglycemia, hyperuricemia (gout), upper GI tract distress, hepatotoxicity</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Fibric acids</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Gemfibrozil</p>
							<p class="table-body">Fenofibrate</p>
							<p class="table-body">Clofibrate</p>
							<p class="table-body">Bezafibrate</p>
							<p class="table-body">Ciprofibrate</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">LDL <span class="symbol">↓</span> 5%–20% (may be increased in patients with high TG)</p>
							<p class="table-body">HDL <span class="symbol">↑</span> 10%–20%</p>
							<p class="table-body">TG <span class="symbol">↓</span> 30%–50%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Dyspepsia, gallstones, myopathy; unexplained non-&#173;CHD deaths in WHO study</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-20">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Cholesterol absorption inhibitor</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Ezetimibe</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">LDL <span class="symbol">↓</span> 14%–17%</p>
							<p class="table-body">HDL <span class="symbol">↑</span> 1%</p>
							<p class="table-body">TG <span class="symbol">↓</span>7–8%</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Myopathy, increased liver enzymes, pos&#173;si&#173;ble increased cancer risk</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-7" colspan="7">
							<p class="table-footnote ParaOverride-8">CHD <span class="symbol">=</span> coronary heart disease; GI <span class="symbol">=</span> gastrointestinal; HDL <span class="symbol">=</span> high-&#173;density lipoprotein; HMG-&#173;CoA <span class="symbol">=</span> 3-&#173;hydroxy-3-&#173;methylglutaryl coenzyme A; LDL <span class="symbol">=</span> low-&#173;density lipoprotein;  TG <span class="symbol">=</span> triglycerides;  WHO <span class="symbol">=</span> World Health Organ&#173;ization; <span class="symbol">↓</span> <span class="symbol">=</span> decrease; <span class="symbol">↑ =</span> increase.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer006" class="Basic-Text-Frame">
			<table id="table003" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-21" />
					<col class="_idGenTableRowColumn-22" />
					<col class="_idGenTableRowColumn-23" />
					<col class="_idGenTableRowColumn-24" />
					<col class="_idGenTableRowColumn-21" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-8" colspan="5">
							<p class="table-title"><span class="table-number">&#173;Table&#160;4-3</span> Intensity of Statin Therapy With Daily Dosing</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" colspan="3">
							<p class="table-head ParaOverride-9">High-&#173;intensity statin therapy (reduces LDL-&#173;C by <span class="symbol">≥</span>50%)</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-indent-2">Atorvastatin 40–80&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-body">Rosuvastatin 20–40&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-26">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" colspan="3">
							<p class="table-head ParaOverride-10">Moderate-intensity statin therapy (reduces LDL-C by 30%–50%)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-indent-2">Atorvastatin 10–20&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body">Pitavastatin 2–4&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-indent-2">Fluvastatin 40&#160;mg twice daily</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body">Pravastatin 40–80&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-indent-2">Fluvastatin XL 80&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body">Rosuvastatin 5–10&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-2">Lovastatin 40&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-body">Simvastatin 20–40&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-11" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table CellOverride-7" colspan="5">
							<p class="table-source-note">Modified with permission from Stone NJ, Robinson JG, Lichtenstein AH, et&#160;al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <span class="table-italic">J Am Coll Cardiol.</span> 2014;63(25 Pt B):2889–2934.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer007" class="Basic-Text-Frame">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer008" class="Basic-Text-Frame">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer009" class="Basic-Text-Frame">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer010" class="Basic-Text-Frame">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer011" class="Basic-Text-Frame">
			</div>
		</div>
	</body>
</html>
